Prognostic Value of Antibodies in Breast Cancer
Author Information
Author(s): I.M. Muir, R.G. Reed, S.A. Stacker, A.I. Alexander, I.F.C. McKenzie, R.C. Bennett
Primary Institution: Melbourne University Department of Surgery, St. Vincent's Hospital
Hypothesis
Can immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 provide prognostic information in breast cancer?
Conclusion
Immunoperoxidase staining patterns with NCRC-11 and 3E1.2 are important prognostic factors in breast cancer, especially in lymph node negative patients.
Supporting Evidence
- NCRC-11 staining score related to survival in all 483 cases.
- Both antibodies achieved maximum prognostic significance in lymph node negative patients.
- Staining score with both MoAbs was strongly related to hormone receptor status.
Takeaway
This study found that certain tests on breast cancer tumors can help doctors predict how well a patient might do, especially if their cancer hasn't spread to the lymph nodes.
Methodology
The study involved staining paraffin sections of 483 primary breast cancers with NCRC-11 and 3E1.2 and comparing the staining patterns with overall survival using life tables and Cox's multivariate analysis.
Limitations
The study did not standardize treatment and lacked data on radiotherapy or chemotherapy effects.
Participant Demographics
Women with primary breast cancer treated in Victoria, Australia, between 1976 and 1981.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.002
Want to read the original?
Access the complete publication on the publisher's website